Previous 10 | Next 10 |
Psychedelics are on the cusp of a major boom, and could soon go mainstream. With US FDA support, clinical research studies, and legalization in Oregon, it may only be a matter of time before other states begin to join in. In fact, there are reports California could decriminalize it, too. Ac...
London, UK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in two investor confer...
Psychedelics such as psilocybin could soon revolutionize the $2.5 trillion mental health market. All thanks to some big catalysts. For one, “Traditional medicines that are treating things like depression, addiction and anxiety really are seeking to numb and mask the issues that surro...
2020’s United States Presidential election night was a potential tipping point for easing regulations on psychoactive drugs. In clinical studies, psilocybin has been shown to be effective in treating mental health issues such as depression, anxiety, obsessive-compulsive disorde...
The psilocybin story could heat up in New Year 2021. For one, the US FDA appears to be supportive of psilocybin research. Two, clinical studies from institutions such as Johns Hopkins Medicine, and New York University appear to be showing positive study results using psychedelics. Three, as...
Palm Beach, FL – December 23, 2020 – The cognitive assessment and training in healthcare market is positioned to have significant growth through the next several years. Cognitive assessment evaluates important areas of brain function. These areas include memory, concentration,...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 21, 2020 – Investments continued flowing into the psychedelic medicine sector this year and will likely continue in 2021 as mental illness cases rise across the globe. The World...
Compass Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depression. Received the highly-valuable FDA Breakthrough Therapy Designation for COMP360 trials and...
With psychedelic drugs showing promise with mental health issues, investors have just begun to push into a space that could be worth up to $100 billion, according to Tania Gonsalves, analyst for Canaccord Genuity Capital Markets, as quoted by Psychedlic Spotlight. She added, “the com...
COMPASS Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depression. Received the highly-valuable FDA Breakthrough Therapy Designation for COMP360 trials and...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...